Skip to main content

Table 1 Segmented regression analysis on monthly adjusted number of prescription of the six antihypertensive drug classes

From: The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Variables β1(a) β2(b) β3(c) β4(d) β5(e) β6(f) β7(g)
ACEIs prescription proportion (%) −0.02 (−0.2, −0.01) −0.30 (−0.44, −0.16) 0.013 (0.007, 0.02) --- --- --- ---
Adjusted number of prescriptions
  ACEIs 135.7 (117.8, 153.6) --- −149.9 (−181.4, −118.4) --- --- --- ---
  ARBs 65.9 (58.7, 72.0) --- −67.2 (−79.8, −54.6) --- --- --- ---
  Diuretics −55.4 (−61.9, −48.9) --- --- --- --- --- ---
  CCBs 90.4 (77.0, 103.9) --- −77.4 (−101.1, −53.8) --- --- --- ---
  BBs −102.7 (−119.0, −86.5) --- −75.3 (−98.3, −52.4) --- --- --- ---
  “Others” −3.0 (−4.9, −1.0) --- −15.6 (−21.1, −10.1) --- --- --- ---
  1. Regression coefficients (95 % confidence intervals) for the final model (the most parsimonious models); (a)baseline trend; (b)level change following BCBV policy; (c)trend change following BCBV policy; (d)level change following generic losartan availability; (e)trend change following generic losartan availability; (f)level change following generic perindopril availability; (g)trend change following generic perindopril availability; −--: indicates insignificant estimates at 0.05 level, after stepwise backward elimination; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers; CCBs: Calcium channel blockers; BBs: Beta-blocker